Innovate, Involve, Inspire

Launched by FRONTLINE AIDS · Sep 17, 2024

Keywords

ClinConnect Summary

The "Innovate, Involve, Inspire" clinical trial is looking to improve how we test and treat Hepatitis C Virus (HCV) in the community. The study will use a simplified testing and treatment process at local sites, such as harm reduction centers, to make it easier for people to get help. If someone tests positive for HCV, they will have additional tests to confirm the diagnosis. Those who qualify for the study will receive a combination medication called sofosbuvir/daclatasvir, which helps treat HCV.

To be eligible for this trial, participants must be at least 18 years old, have used drugs in the last 90 days, and test positive for HCV RNA (a marker of active infection). The study is not yet recruiting participants, but once it starts, those who join can expect to be monitored closely after their treatment, with follow-up tests to see if the virus is gone 12 weeks after finishing the medication. This trial aims to make HCV treatment more accessible and effective, helping many people in the community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Drug use in the past 90 days
• • Age 18 and above
• • Positive for HCV RNA
• Exclusion Criteria:
• • No meeting inclusion criteria
• • Pregnancy